The Hol Picture

At Holmusk, our vision is to provide fit-for-purpose real-world data that fuel research and innovation in behavioral health. With tons of data captured each day as patients move through healthcare systems—much of it in unstructured data fields—a lot goes on behind the scenes, as we ensure that this information is available and usable for research. Below, you’ll find a quick overview on the types of data that are included in the NeuroBlu Database—as well as the process data go through to ensure they are fit-for-purpose.

With so many types of real-world data available, it can be difficult to select the source that will meet your needs—that is, the data that will help you accurately and efficiently answer your research questions.

Earlier this month,  the Substance Abuse and Mental Health Services Administration (SAMHSA) released its annual National Survey on Drug Use and Health (NSDUH), which examined substance use and mental health data from 2021. Although the survey has been administered since 1971, SAMHSA called this year’s “the most comprehensive report on substance use and mental health indicators” that the organization has released to date.

This blog post is a continuation of our Data Differentiators series, in which we’re sharing how the NeuroBlu Database stands out from other EHR-derived real-world data sources. For previous installments of the series, see here and here.

This blog post is a continuation of our Data Differentiators series, in which we’re sharing how the NeuroBlu Database stands out from other EHR-derived real-world data sources. For previous installments of the series, see here.

Our mission is to build the world’s richest real-world evidence platform for behavioral health to transform clinical research and care delivery. Our NeuroBlu Database delivers value to our customers by providing meaningful clinical information that helps to produce evidence that could not be easily generated otherwise.

This year at the American Society of Clinical Psychopharmacology’s annual conference, I had the privilege to organize and chair a panel discussion on challenges and opportunities in leveraging real-world evidence to inform the development of new treatments in behavioral health.

Each May, the National Alliance on Mental Illness (NAMI) recognizes Mental Health Awareness Month. While awareness is certainly an important component of tackling our nation’s mental health crisis, the theme chosen this year by NAMI highlights that more than just awareness is needed. It is time to come “Together for Mental Health” and to take action to transform the mental health care ecosystem.

Last week, I had the pleasure of being invited to present at the monthly COVID-19 Evidence Accelerator, which is hosted by the Reagan-Udall Foundation for the FDA, the FDA, and Friends of Cancer Research. This month’s conversation was a continuation of an ongoing discussion about the impacts the pandemic has had and continues to have on mental health.